DNTH
Dianthus Therapeutics, Inc.$82.43+0.05 (+0.06%)Prev Close$82.38·MCap$4.61B·P/E112.19·Vol266.5K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
20
$71.20M
◆
Net Activity
Net Seller
$71.20M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Dianthus Therapeutics, Inc. (DNTH) has been exclusively selling, with 0 insider purchases totaling $0.00 and 20 insider sales totaling $71.20M. The most recent insider transaction was by CARR EDWARD (officer: CHIEF ACCOUNTING OFFICER), who sold $2.03M worth of shares on Sep 18, 2026. Dianthus Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.61B.
DNTH Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | CARR EDWARD | officer: CHIEF ACCOUNTING OFFICER | Sell | 20,000 | $101.38 | $2.03M | 12,072-62% |
| Sep 3, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 23,124 | $106.41 | $2.46M | 24,524-49% |
| Aug 19, 2026 | Read Simon | director | Sell | 2,778 | $117.55 | $326.6K | 0Exit |
| Aug 11, 2026 | Read Simon | director | Sell | 2,777 | $109.55 | $304.2K | 2,707-51% |
| Aug 11, 2026 | McGeorge Anne | director | Sell | 7,750 | $109.01 | $844.8K | 6,300-55% |
| Aug 11, 2026 | Veness Adam M | officer: SVP, General Counsel and Sec. | Sell | 20,000 | $110.44 | $2.21M | 616-97% |
| Aug 7, 2026 | Garcia Marino | director, officer: CEO AND PRESIDENT | Sell | 166,000 | $108.11 | $17.95M | 220,908-43% |
| Jul 13, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 31,249 | $101.03 | $3.16M | 20,895-60% |
| Jun 18, 2026 | Veness Adam M | officer: SVP, General Counsel and Sec. | Sell | 30,000 | $80.80 | $2.42M | 13,229-69% |
| Jun 2, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 26,530 | $90.62 | $2.40M | 25,102-51% |
| May 11, 2026 | Soteropoulos Paula | director | Sell | 599 | $85.47 | $51.2K | 0Exit |
| Apr 10, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 8,224 | $89.84 | $738.8K | 0Exit |
| Apr 1, 2026 | Soteropoulos Paula | director | Sell | 599 | $80.11 | $48.0K | 0Exit |
| Apr 1, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 114,367 | $83.00 | $9.49M | 112,977-50% |
| Mar 26, 2026 | Soteropoulos Paula | director | Sell | 27,594 | $78.05 | $2.15M | 0Exit |
| Mar 13, 2026 | CARR EDWARD | officer: CHIEF ACCOUNTING OFFICER | Sell | 43,682 | $81.49 | $3.56M | 27,830-61% |
| Mar 13, 2026 | Garcia Marino | director, officer: CEO AND PRESIDENT | Sell | 122,918 | $81.49 | $10.02M | 79,413-61% |
| Mar 13, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 33,830 | $81.48 | $2.76M | 0Exit |
| Dec 4, 2025 | Savitz Ryan | CFO & CBO | Sell | 20,000 | $45.18 | $903.6K | 0 |
| Nov 13, 2025 | Randhawa Simrat | EVP, Head of R&D | Sell | 196,538 | $37.55 | $7.38M0.5% OS | 0 |
| Sep 9, 2025 | Savitz Ryan | CFO & CBO | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Oct 3, 2023 | Fairmount Funds Management LLC | Director | Buy | 24,670 | $13.63 | $336.3K | 1,928,503 |
| Sep 28, 2023 | Fairmount Funds Management LLC | Director | Buy | 30,000 | $13.15 | $394.5K | 1,903,833 |
| Sep 25, 2023 | Randhawa Simrat | Chief Medical Officer | Buy | 4,000 | $13.20 | $52.8K | 4,000 |
| Sep 21, 2023 | Fairmount Funds Management LLC | Director | Buy | 30,000 | $13.20 | $396.0K | 1,873,833 |
| Sep 13, 2023 | Fairmount Funds Management LLC | Buy | 24,254 | $11.20 | $271.7K | 1,843,833 | |
| Feb 9, 2023 | Third Rock Ventures IV, L.P. | 10% Owner | Sell | 3,700,000 | $0.83 | $3.06M9.6% OS | 4,558,204-45% |
| Sep 20, 2021 | Beetham Thomas W. | See Remarks | Sell | 6,103 | $6.73 | $41.1K | 13,897-31% |
| Sep 20, 2021 | Deardorf Caren | Chief Commercial Officer | Sell | 6,238 | $6.73 | $42.0K | 13,762-31% |
| Sep 20, 2021 | GARDNER JASON | See Remarks | Sell | 14,340 | $6.73 | $96.5K | 286,872 |
| Sep 20, 2021 | Nichols David Wayne | Chief Technical Officer | Sell | 5,694 | $6.73 | $38.3K | 14,306-28% |
| Sep 20, 2021 | Stants Kristen | Chief People Officer | Sell | 5,736 | $6.73 | $38.6K | 14,264-29% |
DNTH Insider Buying Activity
The following table shows recent insider purchases of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 3, 2023 | Fairmount Funds Management LLC | Director | Buy | 24,670 | $13.63 | $336.3K | 1,928,503 |
| Sep 28, 2023 | Fairmount Funds Management LLC | Director | Buy | 30,000 | $13.15 | $394.5K | 1,903,833 |
| Sep 25, 2023 | Randhawa Simrat | Chief Medical Officer | Buy | 4,000 | $13.20 | $52.8K | 4,000 |
| Sep 21, 2023 | Fairmount Funds Management LLC | Director | Buy | 30,000 | $13.20 | $396.0K | 1,873,833 |
| Sep 13, 2023 | Fairmount Funds Management LLC | Buy | 24,254 | $11.20 | $271.7K | 1,843,833 |
DNTH Insider Selling Activity
The following table shows recent insider sales of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | CARR EDWARD | officer: CHIEF ACCOUNTING OFFICER | Sell | 20,000 | $101.38 | $2.03M | 12,072-62% |
| Sep 3, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 23,124 | $106.41 | $2.46M | 24,524-49% |
| Aug 19, 2026 | Read Simon | director | Sell | 2,778 | $117.55 | $326.6K | 0Exit |
| Aug 11, 2026 | Read Simon | director | Sell | 2,777 | $109.55 | $304.2K | 2,707-51% |
| Aug 11, 2026 | McGeorge Anne | director | Sell | 7,750 | $109.01 | $844.8K | 6,300-55% |
| Aug 11, 2026 | Veness Adam M | officer: SVP, General Counsel and Sec. | Sell | 20,000 | $110.44 | $2.21M | 616-97% |
| Aug 7, 2026 | Garcia Marino | director, officer: CEO AND PRESIDENT | Sell | 166,000 | $108.11 | $17.95M | 220,908-43% |
| Jul 13, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 31,249 | $101.03 | $3.16M | 20,895-60% |
| Jun 18, 2026 | Veness Adam M | officer: SVP, General Counsel and Sec. | Sell | 30,000 | $80.80 | $2.42M | 13,229-69% |
| Jun 2, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 26,530 | $90.62 | $2.40M | 25,102-51% |
| May 11, 2026 | Soteropoulos Paula | director | Sell | 599 | $85.47 | $51.2K | 0Exit |
| Apr 10, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 8,224 | $89.84 | $738.8K | 0Exit |
| Apr 1, 2026 | Soteropoulos Paula | director | Sell | 599 | $80.11 | $48.0K | 0Exit |
| Apr 1, 2026 | Savitz Ryan | officer: EVP, CFO & CBO | Sell | 114,367 | $83.00 | $9.49M | 112,977-50% |
| Mar 26, 2026 | Soteropoulos Paula | director | Sell | 27,594 | $78.05 | $2.15M | 0Exit |
| Mar 13, 2026 | CARR EDWARD | officer: CHIEF ACCOUNTING OFFICER | Sell | 43,682 | $81.49 | $3.56M | 27,830-61% |
| Mar 13, 2026 | Garcia Marino | director, officer: CEO AND PRESIDENT | Sell | 122,918 | $81.49 | $10.02M | 79,413-61% |
| Mar 13, 2026 | Randhawa Simrat | officer: EVP, Head of R&D | Sell | 33,830 | $81.48 | $2.76M | 0Exit |
| Dec 4, 2025 | Savitz Ryan | CFO & CBO | Sell | 20,000 | $45.18 | $903.6K | 0 |
| Nov 13, 2025 | Randhawa Simrat | EVP, Head of R&D | Sell | 196,538 | $37.55 | $7.38M0.5% OS | 0 |
| Sep 9, 2025 | Savitz Ryan | CFO & CBO | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Feb 9, 2023 | Third Rock Ventures IV, L.P. | 10% Owner | Sell | 3,700,000 | $0.83 | $3.06M9.6% OS | 4,558,204-45% |
| Sep 20, 2021 | Beetham Thomas W. | See Remarks | Sell | 6,103 | $6.73 | $41.1K | 13,897-31% |
| Sep 20, 2021 | Deardorf Caren | Chief Commercial Officer | Sell | 6,238 | $6.73 | $42.0K | 13,762-31% |
| Sep 20, 2021 | GARDNER JASON | See Remarks | Sell | 14,340 | $6.73 | $96.5K | 286,872 |
| Sep 20, 2021 | Nichols David Wayne | Chief Technical Officer | Sell | 5,694 | $6.73 | $38.3K | 14,306-28% |
| Sep 20, 2021 | Stants Kristen | Chief People Officer | Sell | 5,736 | $6.73 | $38.6K | 14,264-29% |
DNTH Insiders
Similar Stocks to DNTH
MRNA
Moderna, Inc.
$227.10+2.43%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$963.34+3.82%
$83.15B
RVMD
Revolution Medicines, Inc.
$189.18-1.12%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$160.28-2.86%
$30.46B
UTHR
United Therapeutics Corporation
$596.63-0.35%
$25.15B
INCY
Incyte Corporation
$119.33-0.88%
$23.69B
INSM
Insmed Incorporated
$110.27-2.06%
$21.18B
EXEL
Exelixis, Inc.
$71.30+2.67%
$16.64B